Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.

Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.

With more than 3 million proven infections and 100.000 associated deaths in Italy, the COVID-19 pandemic poses extraordinary challenges to health-care professionals and especially to those caring for patients with haematologic malignancies  (1-2). Given the multiple   immune  defects characterizing...

Full description

Bibliographic Details
Main Authors: Stefano Molica, Paolo Sportoletti, Nicola Di Renzo, Pellegrino Musto, Fabrizio Pane, Francesco Di Raimondo
Format: Article
Language:English
Published: PAGEPress Publications 2021-06-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Subjects:
CLL, symptomatic COVID19 , Venetoclax-rituximab, time-limited therapy
Online Access:https://www.mjhid.org/index.php/mjhid/article/view/4613

Internet

https://www.mjhid.org/index.php/mjhid/article/view/4613

Similar Items